Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$48K Buy
714
+520
+268% +$34.6K 0.03% 798
2026
Q1
$12K Sell
194
-49
-20% -$3.41K 0.01% 1314
2025
Q4
$16K Sell
243
-13
-5% -$840 0.01% 1370
2025
Q3
$17K Sell
256
-297
-54% -$23.5K 0.01% 1331
2025
Q2
$48K Sell
553
-324
-37% -$25.4K 0.03% 900
2025
Q1
$60K Sell
877
-232
-21% -$18.9K 0.04% 767
2024
Q4
$86K Buy
1,109
+150
+16% +$11.1K 0.05% 608
2024
Q3
$64K Buy
959
+335
+54% +$27.5K 0.04% 765
2024
Q2
$71K Sell
624
-225
-27% -$28.4K 0.05% 694
2024
Q1
$118K Buy
849
+15
+2% +$1.89K 0.07% 423
2023
Q4
$104K Buy
834
+541
+185% +$55.3K 0.07% 469
2023
Q3
$27K Sell
293
-276
-49% -$31.1K 0.02% 1009
2023
Q2
$73K Buy
569
+390
+218% +$47.2K 0.06% 607
2023
Q1
$21K Buy
179
+7
+4% +$784 0.02% 982
2022
Q4
$20K Hold
172
0.02% 1030
2022
Q3
$14K Sell
172
-3
-2% -$254 0.01% 1118
2022
Q2
$13K Sell
175
-9
-5% -$821 0.01% 1109
2022
Q1
$24K Sell
184
-344
-65% -$37.6K 0.02% 1009
2021
Q4
$71K Buy
+528
New +$75.9K 0.1% 331

Other funds holding DXCM

Covestor's DXCM Position: Q2 2026 in Review

Covestor increased its DexCom (DXCM) stake by 268% in Q2 2026, buying an estimated $34.6K and bringing the position to 714 shares worth $48K. The position accounts for 0.03% of the portfolio, ranked #798.

Covestor first reported a position in DXCM in Q4 2021 and has held it in 19 quarters since. The position peaked at $118K in Q1 2024. 585 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Covestor held 714 shares of DexCom worth $48K as of Q2 2026.
  • Covestor bought 520 DexCom shares in Q2 2026, an estimated $34.6K.
  • DexCom made up 0.03% of Covestor's portfolio in Q2 2026, its #798 holding.
  • Covestor first reported a position in DexCom in Q4 2021 and has held it in 19 quarters since.
  • Covestor's DexCom position peaked at $118K in Q1 2024.
  • 585 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.